Clinical Trial Update: Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Days [Phase 3]

View source ↗

Summary

Phase 3 trial assessing the safety, tolerability, and pharmacokinetics of orally administered tecovirimat (TPOXX) over 28 days for smallpox; results have been p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Smallpox

Drugs mentioned

• TPOXX (tecovirimat monohydrate)

Snippet

Sponsor: SIGA Technologies | Conditions: Smallpox | Phase 3 | Status: COMPLETED | Results posted: 2024-10-23